Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Biogen

TECFIDERA revenues up 9% to $4.0 billion

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen

4Q Revenues: $2.9 billion (+1%)

4Q Earnings: $649 million (-22%)

FY Revenues: $11.4 billion (+6%)

FY Earnings: $3.7 billion (+4%)

Comments: Growth was driven by TECFIDERA revenues ($4.0 billion, up 9%); TYSABRI ($2.0 billion, up 4%); ELOCTATE ($513 million, up 61%); ALPROLIX ($334 million, up 42%); as well as BENEPALI, an etanercept biosimilar commercialized in Europe. Revenues were partially offset by a decrease in worldwide interferon sales. Earnings were negatively impacted by $339 million related to the settlement and license agreement with Forward Pharma A/S. R&D expenses were flat at $2.0 billion. Restructuring charges twelve months ended December 31, 2016, include charges of $17.7 million, in connection with additional cost savings measures intended to realign the company’s organizational structure in anticipation of the changes in roles and workforce resulting from the decision to spin off its hemophilia business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters